Omega-3 Fatty Acid Suppression of Silica-induced Inflammasome Activation in a Novel Alveolar Macrophage Model
Omega-3 脂肪酸在新型肺泡巨噬细胞模型中抑制二氧化硅诱导的炎症小体激活
基本信息
- 批准号:9758932
- 负责人:
- 金额:$ 3.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-16 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAlveolar MacrophagesAnti-inflammatoryAttenuatedAutoimmune DiseasesAutoimmune ProcessAutoimmunityBindingCell DeathCell LineCell NucleusCell membraneCellsCharacteristicsChemicalsChronicComplexDataDevelopmentDietDietary FatsDietary SupplementationDiseaseDocosahexaenoic AcidsDoseDustEnvironmentEnzymesEtiologyEventExposure toFamilyFatty AcidsFetal LiverFish OilsG-Protein-Coupled ReceptorsGenesGoalsGranulocyte-Macrophage Colony-Stimulating FactorHumanImmuneIn VitroInflammasomeInflammationInflammation MediatorsInflammatoryInhalationInnate Immune ResponseInnate Immune SystemInstitutesInterleukin-1Interleukin-1 betaInterventionKnowledgeLaboratoriesLeadLearningLinkLipidsLipoxygenaseLiteratureLiverLungLung diseasesLupusMeasuresMediatingMediator of activation proteinMissionModelingMolecularMusNF-kappa BNational Institute of Environmental Health SciencesNuclear TranslocationOmega-3 Fatty AcidsPatientsPhenotypePhospholipidsPlanet EarthPlayPre-Clinical ModelQuartzResearch PersonnelResourcesRoleSignal PathwaySignal TransductionSilicon DioxideSmall Interfering RNASupplementationSystemSystemic Lupus ErythematosusTestingToxic Environmental SubstancesToxic effectToxicant exposureTrainingUnsaturated Fatty AcidsUp-Regulationairway inflammationattenuationautocrinecrystallinitycytokinedisabilityexperimental studyfetalgrasphuman diseaseimprovedinhibitor/antagonistknock-downlipid mediatorlung injurylupus prone micemacrophagemanmouse modelnovelparacrinepreventreceptorresponseself-renewalsupportive environmenttooltoxicanttranscription factorward
项目摘要
ABSTRACT
The exposome plays a critical role in the development of autoimmune and inflammatory diseases. In this pro-
posal, I will address the role of the dietary ω-3 fatty acid docosahexaenoic acid (DHA) in protecting against
inflammation induced by the respirable toxicant crystalline silica (cSiO2). Previously, our laboratory found that
supplementation with DHA dose-dependently decreased levels of several features of cSiO2-triggered autoim-
munity in a lupus-prone mouse model. A key event in the development of systemic inflammation in this model is
cSiO2-induced toxicity of the alveolar macrophage (AMph), which involves activation of the NLRP3 inflam-
masome and release of potent IL-1 cytokines. The current literature and my preliminary experiments suggest
that DHA and its metabolites, known as specialized proresolving mediators (SPMs), may attenuate this re-
sponse. Activation of the NLRP3 inflammasome, which is implicated in many inflammatory and autoimmune
conditions, requires an initial priming step, during which NF-kB family transcription factors upregulate inflam-
masome components and pro-IL-1 cytokines. Anti-inflammatory G-protein coupled receptors (GPCRs) have
been identified that bind DHA or SPMs and inhibit NF-kB activation. However, in vitro elucidation of the molecular
events of DHA protection in AMph is limited by the low number of cells attainable from a single mouse (~105).
To address this, I used Max Planck Institute (MPI) cells. MPI cells are a self-renewing macrophage cell line
derived by culturing fetal mouse livers in GM-CSF-supplemented medium and are phenotypically similar to
AMph. My preliminary data show that IL-1 cytokine release in response to LPS-priming and cSiO2 treatment is
attenuated by DHA supplementation. I propose that DHA supplementation increases DHA in the cell membrane
of MPI cells, which can be released and metabolized to SPMs. Free DHA and its SPMs can activate anti-inflam-
matory GPCRs in an autocrine or paracrine manner to attenuate NF-kB signaling, which I hypothesize is a pri-
mary mechanism by which they protect against cSiO2-induced inflammation. In Aim 1, the phospholipid incorpo-
ration of DHA will be measured, and then effects of DHA on IL-1 cytokine release and NF-kB activation will be
assessed. I will also treat cells with chemical agonists, antagonists, and siRNA for specific GPCRs to verify their
role in DHA signaling. In Aim 2, the lipid metabolite profile of cells supplemented with DHA will be measured. I
will then determine the extent to which SPMs suppress NF-kB activation and IL-1 cytokine release. Lastly, chem-
ical antagonists and siRNA will be used to investigate the involvement of proposed SPM receptors. These ex-
periments will be performed in a supportive environment with the necessary resources to accomplish these ob-
jectives. My comprehensive training plan provides personal and professional development, which will assist me
in becoming a successful independent researcher.
摘要
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kathryn Alexandria Wierenga其他文献
Kathryn Alexandria Wierenga的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kathryn Alexandria Wierenga', 18)}}的其他基金
Omega-3 Fatty Acid Suppression of Silica-induced Inflammasome Activation in a Novel Alveolar Macrophage Model
Omega-3 脂肪酸在新型肺泡巨噬细胞模型中抑制二氧化硅诱导的炎症小体激活
- 批准号:
9926082 - 财政年份:2019
- 资助金额:
$ 3.58万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 3.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 3.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 3.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)